Display options
Cite
Crocetti E, Mattioli V, Buzzoni C, et al. Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012. Cancer Med. 2021;10(19):6855-6867doi: 10.1002/cam4.4193.
Crocetti, E., Mattioli, V., Buzzoni, C., Franceschi, S., Serraino, D., Vaccarella, S., Ferretti, S., Busco, S., Fedeli, U., Varvarà, M., Falcini, F., Zorzi, M., Carrozzi, G., Mazzucco, W., Gasparotti, C., Iacovacci, S., Toffolutti, F., Cavallo, R., Stracci, F., Russo, A. G., Caldarella, A., Rosso, S., Musolino, A., Mangone, L., Casella, C., Fusco, M., Tagliabue, G., Piras, D., Tumino, R., Guarda, L., Dinaro, Y. M., Piffer, S., Pinna, P., Mazzoleni, G., Fanetti, A. C., Dal Maso, L. (2021). Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012. Cancer medicine, 10(19), 6855-6867. https://doi.org/10.1002/cam4.4193
Crocetti, Emanuele, et al. "Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012." Cancer medicine vol. 10,19 (2021): 6855-6867. doi: https://doi.org/10.1002/cam4.4193
Crocetti E, Mattioli V, Buzzoni C, Franceschi S, Serraino D, Vaccarella S, Ferretti S, Busco S, Fedeli U, Varvarà M, Falcini F, Zorzi M, Carrozzi G, Mazzucco W, Gasparotti C, Iacovacci S, Toffolutti F, Cavallo R, Stracci F, Russo AG, Caldarella A, Rosso S, Musolino A, Mangone L, Casella C, Fusco M, Tagliabue G, Piras D, Tumino R, Guarda L, Dinaro YM, Piffer S, Pinna P, Mazzoleni G, Fanetti AC, Dal Maso L. Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012. Cancer Med. 2021 Oct;10(19):6855-6867. doi: 10.1002/cam4.4193. Epub 2021 Sep 17. PMID: 34533289; PMCID: PMC8495271.
Copy Download .nbib Format: NLM
Share it on

Cancer Med. 2021 Oct;10(19):6855-6867. doi: 10.1002/cam4.4193. Epub 2021 Sep 17.

Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012.

Cancer medicine

Emanuele Crocetti, Veronica Mattioli, Carlotta Buzzoni, Silvia Franceschi, Diego Serraino, Salvatore Vaccarella, Stefano Ferretti, Susanna Busco, Ugo Fedeli, Massimo Varvarà, Fabio Falcini, Manuel Zorzi, Giuliano Carrozzi, Walter Mazzucco, Cinzia Gasparotti, Silvia Iacovacci, Federica Toffolutti, Rossella Cavallo, Fabrizio Stracci, Antonio G Russo, Adele Caldarella, Stefano Rosso, Antonino Musolino, Lucia Mangone, Claudia Casella, Mario Fusco, Giovanna Tagliabue, Daniela Piras, Rosario Tumino, Linda Guarda, Ylenia M Dinaro, Silvano Piffer, Pasquala Pinna, Guido Mazzoleni, Anna C Fanetti, Luigino Dal Maso,

Affiliations

  1. Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  2. Global Patient Outcomes and Real World Evidence (GPORWE) International Eli Lilly Italy S.p.A, Sesto Fiorentino, Florence, Italy.
  3. AIRTUM Database (in charge until January 2019), Florence, Italy.
  4. Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
  5. Romagna Cancer Registry, Section of Ferrara, Local Health Unit, University of Ferrara, Ferrara, Italy.
  6. Cancer Registry of Latina Province, ASL Latina, Latina, Italy.
  7. Epidemiological Department, Azienda Zero, Padua, Italy.
  8. Registro Tumori Integrato Catania-Messina-Siracusa-Enna, Università degli Studi di Catania, Catania, Italy.
  9. Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.
  10. Veneto Tumor Registry, Azienda Zero, Padua, Italy.
  11. Modena Cancer Registry, Public Health Department, AUSL Modena, Modena, Italy.
  12. Palermo and Province Cancer Registry, Clinical Epidemiology Unit with Cancer Registry, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone", University of Palermo, Palermo, Italy.
  13. Brescia Cancer Registry, Epidemiology Unit, Brescia Health Protection Agency, Brescia, Italy.
  14. ASL Salerno Cancer Registry, Salerno, Italy.
  15. Public Health Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
  16. Cancer Registry of Milan, Epidemiology Unit, Agency for Health Protection, Milan, Italy.
  17. Tuscany Cancer Registry, Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
  18. Piedmont Cancer Registry, Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, Italy.
  19. Parma Cancer Registry, Oncology Unit, Azienda Ospedaliera Universitaria di Parma, Parma, Italy.
  20. Reggio Emilia Cancer Registry, Epidemiology Unit, AUSL ASMN-IRCCS, Azienda USL di Reggio Emilia, Reggio Emilia, Italy.
  21. Liguria Cancer Registry, Clinical Epidemiology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  22. Cancer Registry of ASL Napoli 3 Sud, Napoli, Italy.
  23. Lombardy Cancer Registry, Cancer Registry Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  24. North Sardinia Cancer Registry, Azienda Regionale per la Tutela della Salute, Sassari, Italy.
  25. Cancer Registry and Histopathology Department, Provincial Health Authority (ASP 7), Ragusa, Italy.
  26. Mantova Cancer Registry, Epidemilogy Unit, Agenzia di Tutela della Salute (ATS) della Val Padana, Mantova, Italy.
  27. Siracusa Cancer Registry, Health Unit of Siracusa, Siracusa, Italy.
  28. Trento Province Cancer Registry, Unit of Clinical Epidemiology, Trento, Italy.
  29. Nuoro Cancer Registry, RT Nuoro, ASSL Nuoro/ATS Sardegna, Nuoro, Italy.
  30. Southtyrol Cancer Registry, Bolzano, Italy.
  31. Sondrio Cancer Registry, Health Protection Agency, Sondrio, Italy.

PMID: 34533289 PMCID: PMC8495271 DOI: 10.1002/cam4.4193

Abstract

BACKGROUND: The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC.

METHODS: We analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer.

RESULTS: A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12-1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42-1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon-rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers.

CONCLUSIONS: The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Keywords: Italy; cancer survivors; population-based cancer registries; relative risk; second primary cancer; thyroid cancer

References

  1. Thyroid. 2015 Dec;25(12):1330-8 - PubMed
  2. Epidemiol Prev. 2013 Jul-Oct;37(4-5 Suppl 1):1-152 - PubMed
  3. Thyroid. 2018 Dec;28(12):1662-1673 - PubMed
  4. Nat Rev Clin Oncol. 2016 Sep;13(9):550-65 - PubMed
  5. Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):643-649 - PubMed
  6. Eur J Cancer. 2018 May;94:6-15 - PubMed
  7. Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36 - PubMed
  8. Breast Cancer Res Treat. 2015 Jul;152(1):173-181 - PubMed
  9. Epidemiol Prev. 2017 Mar-Apr;41(2 Suppl 1):1-244 - PubMed
  10. N Engl J Med. 2016 Aug 18;375(7):614-7 - PubMed
  11. J Public Health (Oxf). 2018 Jun 1;40(2):e91-e98 - PubMed
  12. BMC Cancer. 2011 Feb 23;11:83 - PubMed
  13. Thyroid. 2017 Jun;27(6):793-801 - PubMed
  14. Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):231-8 - PubMed
  15. Cancer Epidemiol. 2020 Feb;64:101664 - PubMed
  16. Ann Surg Oncol. 2013 Apr;20(4):1341-7 - PubMed
  17. Nat Rev Endocrinol. 2018 Sep;14(9):538-551 - PubMed
  18. Med J Aust. 2020 Mar;212(4):163-168 - PubMed
  19. Lancet Diabetes Endocrinol. 2020 Jun;8(6):468-470 - PubMed
  20. Epidemiol Health. 2015 Mar 07;37:e2015015 - PubMed
  21. Br J Cancer. 2003 Nov 3;89(9):1638-44 - PubMed
  22. Cancer. 2011 Oct 1;117(19):4439-46 - PubMed
  23. J Thyroid Res. 2018 Jun 26;2018:8765369 - PubMed
  24. Cancer Med. 2021 Oct;10(19):6855-6867 - PubMed
  25. J Clin Oncol. 2018 Jun 20;36(18):1831-1839 - PubMed
  26. Lancet Diabetes Endocrinol. 2021 Mar;9(3):144-152 - PubMed
  27. BMC Cancer. 2020 Jan 21;20(1):51 - PubMed
  28. World J Urol. 2021 Jan 25;: - PubMed
  29. JAMA. 2020 Dec 22;324(24):2521-2535 - PubMed
  30. Thyroid. 2013 May;23(5):575-82 - PubMed
  31. Cancer Sci. 2012 Jun;103(6):1111-20 - PubMed
  32. J Clin Endocrinol Metab. 2006 May;91(5):1819-25 - PubMed
  33. Tumori. 2019 Apr;105(2):121-137 - PubMed
  34. Int J Epidemiol. 2020 Oct 1;49(5):1517-1525 - PubMed
  35. CMAJ. 2012 Jan 10;184(1):E57-69 - PubMed
  36. Ann Surg Oncol. 2012 Jun;19(6):1887-96 - PubMed
  37. Thyroid. 2015 Jun;25(6):681-7 - PubMed
  38. Int J Cancer. 2020 Nov 15;147(10):2838-2846 - PubMed
  39. J Clin Oncol. 2016 Oct 20;34(30):3672-3679 - PubMed
  40. Cancer. 2015 Jan 15;121(2):259-68 - PubMed
  41. J Clin Endocrinol Metab. 2000 May;85(5):1758-64 - PubMed
  42. BMC Cancer. 2018 Feb 9;18(1):169 - PubMed
  43. Surgery. 2016 Jan;159(1):132-40 - PubMed

Publication Types

Grant support